Online citations, reference lists, and bibliographies.

Glucagon‐like Peptide‐1 Receptor Agonists In Type 2 Diabetes Treatment: Are They All The Same?

R. Gentilella, V. Pechtner, A. Corcos, A. Consoli
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Glucagon‐like peptide‐1 (GLP‐1) receptor agonists (RAs) are an important class of drugs with a well‐established efficacy and safety profile in patients with type 2 diabetes mellitus. Agents in this class are derived from either exendin‐4 (a compound present in Gila monster venom) or modifications of human GLP‐1 active fragment. Differences among these drugs in duration of action (ie, short‐acting vs long‐acting), effects on glycaemic control and weight loss, immunogenicity, tolerability profiles, and administration routes offer physicians several options when selecting the most appropriate agent for individual patients. Patient preference is also an important consideration. The aim of this review is to discuss the differences between and similarities of GLP‐1 RAs currently approved for clinical use, focusing particularly on the properties characterising the single short‐acting and long‐acting GLP‐1 RAs rather than on their individual efficacy and safety profiles. The primary pharmacodynamic difference between short‐acting (ie, exenatide twice daily and lixisenatide) and long‐acting (ie, albiglutide, dulaglutide, exenatide once weekly, liraglutide, and semaglutide) GLP‐1 RAs is that short‐acting agents primarily delay gastric emptying (lowering postprandial glucose) and long‐acting agents affect both fasting glucose (via enhanced glucose‐dependent insulin secretion and reduced glucagon secretion in the fasting state) and postprandial glucose (via enhanced postprandial insulin secretion and inhibition of glucagon secretion). Other advantages of long‐acting GLP‐1 RAs include smaller fluctuations in plasma drug concentrations, improved gastrointestinal tolerability profiles, and simpler, more convenient administration schedules (once daily for liraglutide and once weekly for albiglutide, dulaglutide, the long‐acting exenatide formulation, and semaglutide), which might improve treatment adherence and persistence.
This paper references
10.1007/s40262-015-0338-3
Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials
Jeanne S. Geiser (2015)
10.2337/dc14-1625
Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)
F. Giorgino (2015)
10.2337/db07-1775
Protein Engineering Strategies for Sustained Glucagon-Like Peptide-1 Receptor–Dependent Control of Glucose Homeostasis
Kristen M. Picha (2008)
10.1016/S2213-8587(18)30024-X
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
R. Pratley (2018)
10.7326/0003-4819-146-7-200704030-00003
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes
B. Zinman (2007)
10.1016/S2213-8587(13)70214-6
Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study.
R. Pratley (2014)
10.1111/dom.12902
Treatment patterns in patients with type 2 diabetes mellitus treated with glucagon‐like peptide‐1 receptor agonists: Higher adherence and persistence with dulaglutide compared with once‐weekly exenatide and liraglutide
C. Alatorre (2017)
Ozempic (semaglutide) European summary of product characteristics
AS NovoNordisk (2018)
The nausea profile of once weekly dulaglutide 1.5 mg. Poster presented at the American Association of Pharmaceutical Scientists
C Loghin (2015)
10.1007/s40262-015-0343-6
Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
L. Jacobsen (2015)
10.1177/2042018815580257
Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance
S. H. Tella (2015)
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes
PD Home (2015)
10.2337/dc11-1935
Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy
V. Fonseca (2012)
Efficacy and safety of semaglutide once‐weekly vs placebo as add‐on to basal insulin alone or in combination with metformin in subjects with type 2 diabetes (SUSTAIN
H Rodbard (2016)
10.1080/03007995.2018.1448260
Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch® among self-injection-naïve patients with type 2 diabetes mellitus in Japan
T. Asakura (2018)
10.1111/j.1463-1326.2012.01618.x
Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)*
Y. Seino (2012)
malization of fasting hyperglycaemia by exogenous glucagon ‐ like peptide 1 ( 7 ‐ 36 amide ) in type 2 ( non ‐ insulin ‐ dependent ) diabetic patients
JF Mann (1993)
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug‐naive patients with type 2 diabetes (DURATION‐4): a 26‐week double‐blind study
D Russell‐Jones (2012)
10.1016/S0140-6736(10)60590-9
Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
R. Bergenstal (2010)
Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled onMetformin ( GetGoal-M )
B. Ahrén (2013)
10.1111/j.1463-1326.2012.01561.x
Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatment
M. Fineman (2012)
10.1517/17460441.2014.942638
The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus
Mikkel B Christensen (2014)
10.1016/S0140-6736(10)60307-8
Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
R. Pratley (2010)
10.1053/j.gastro.2011.02.018
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
M. Elashoff (2011)
10.2337/db10-0474
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
M. Nauck (2011)
10.1002/dmrr.2810
Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program
J. Jendle (2016)
10.1016/S0140-6736(09)60659-0
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
J. Buse (2009)
10.1016/S2213-8587(18)30104-9
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
K. Tuttle (2018)
10.2337/DIACARE.28.5.1092
Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.
R. DeFronzo (2005)
Ozempic (semaglutide) prescribing information
AS NovoNordisk (2018)
10.1111/dom.12076
Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin
C. Kapitza (2013)
10.1185/030079907X253870
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
D. Klonoff (2008)
10.1586/17512433.2016.1141046
Dulaglutide (LY-2189265) for the treatment of type 2 diabetes
A. Scheen (2016)
Victoza (liraglutide) prescribing information. Updated 25 August 2017
AS NovoNordisk (2017)
10.1111/dom.12012
Long‐term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2‐year results from the LEAD‐2 study
M. Nauck (2013)
10.1038/nrendo.2012.140
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
J. Meier (2012)
10.2337/dc08-1355
Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes
M. Nauck (2009)
10.1007/BF00401145
Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients
M. Nauck (1993)
10.1007/s11154-014-9289-5
Effects of GLP-1 on appetite and weight
M. Shah (2014)
10.2337/DIACARE.27.11.2628
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes.
J. Buse (2004)
10.1186/s12933-016-0355-z
Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events
K. Ferdinand (2016)
10.1007/s00125-006-0510-2
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study
M. Nauck (2006)
10.1016/j.bmcl.2013.05.022
Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity.
M. Lorenz (2013)
10.1016/S0140-6736(14)60976-4
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial
K. Dungan (2014)
10.1111/j.1464-5491.2012.03699.x
Exenatide plus metformin compared with metformin alone on β‐cell function in patients with Type 2 diabetes
G. Derosa (2012)
10.1210/en.2009-1272
Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
L. Bjerre Knudsen (2010)
10.1111/dom.12262
A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADD‐ON)
C. Mathieu (2014)
10.1111/dom.12414
Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5
P. Home (2015)
10.7326/0003-4819-143-8-200510180-00006
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes
R. Heine (2005)
10.1056/NEJMOA1607141
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
S. Marso (2016)
10.2337/dc14-2441
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
S. Inzucchi (2014)
10.1111/dom.12382
Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin
J. Reusch (2014)
10.1016/j.mayocp.2015.01.008
Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial.
Carol H Wysham (2015)
10.1007/s10865-007-9147-y
The impact of medication regimen factors on adherence to chronic treatment: a review of literature
K. Ingersoll (2007)
10.1111/dom.12804
A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients
Mirna S. Abd El Aziz (2017)
10.1111/jdi.12457
Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial
Yutaka Seino (2016)
10.1001/jamainternmed.2013.2720
Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
S. Singh (2013)
10.2337/dc13-2760
Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)
C. Wysham (2014)
10.2337/DIACARE.28.5.1083
Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
D. Kendall (2005)
10.2337/dc08-2124
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
B. Zinman (2009)
10.2337/dc09-1914
DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks
J. Buse (2010)
10.2337/dc12-2454
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
M. Riddle (2013)
Victoza (liraglutide) European summary of product characteristics. Updated 7 February 2018
Novo Nordisk (2018)
10.1111/dme.12833
Early fasting glucose measurements can predict later glycaemic response to once weekly dulaglutide
G. Grunberger (2016)
10.1016/S2213-8587(17)30092-X
Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
B. Ahrén (2017)
10.7326/M15-1432
Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments
F. Zaccardi (2016)
10.2337/dc13-2761
Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
M. Nauck (2014)
10.1210/jc.2010-2081
DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
T. Blevins (2011)
10.7326/0003-4819-154-2-201101180-00300
Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes
J. Buse (2011)
10.1056/NEJMp1001578
Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy.
M. Parks (2010)
10.1056/NEJMoa1509225
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
M. Pfeffer (2015)
Byetta (exenatide) prescribing
AB AstraZeneca (2015)
10.2337/dc12-2709
Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin
J. Rosenstock (2013)
10.4158/EP-2018-0108
IN RESPONSE TO AUTHORS' RESPONSE TO KARL Z. NADOLSKY, DO, RE: CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
Alan J. Garber (2018)
10.1177/1932296815583059
Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes
G. Matfin (2015)
10.1007/s00125-009-1472-y
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
D. Russell-Jones (2009)
10.2337/dc14-0001
Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro
J. Rosenstock (2014)
10.1111/dom.12175
Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk: a meta‐analysis of randomized clinical trials
M. Monami (2014)
10.1111/jdi.12607
Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes
H. Kim (2017)
10.1111/j.1464-5491.2009.02666.x
Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
M. Marre (2009)
10.2337/dc12-2462
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine
M. Riddle (2013)
10.1111/dom.12640
Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide
Z. Milicevic (2016)
10.1016/j.ejim.2014.03.005
Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities.
A. Lund (2014)
10.1111/dom.12251
The extra‐pancreatic effects of GLP‐1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
J. Seufert (2014)
10.1177/0091270009354996
Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
E. Watson (2010)
10.1530/EJE-16-0286
Exenatide improves β-cell function up to 3 years of treatment in patients with type 2 diabetes: a randomised controlled trial.
Daniël H van Raalte (2016)
10.2337/dc11-1928
Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets
J. DeVries (2012)
10.1056/NEJMp1314078
Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
A. Egan (2014)
10.2337/dc13-2759
Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3)
G. Umpierrez (2014)
10.1186/1475-2840-10-22
Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
R. Ratner (2011)
10.1016/S0140-6736(08)61246-5
Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
A. Garber (2009)
10.1111/dom.12937
Placebo‐controlled, randomized trial of the addition of once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD‐9)
P. Pozzilli (2017)
10.1111/j.1463-1326.2011.01364.x
A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes
P. Barrington (2011)
10.1111/dme.12128
Real‐world factors affecting adherence to insulin therapy in patients with Type 1 or Type 2 diabetes mellitus: a systematic review
M. Davies (2013)
10.1016/S0140-6736(10)60406-0
Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
M. Diamant (2010)
10.1002/dmrr.2541
Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double‐blind, placebo‐controlled, 24‐week trial (GetGoal‐M‐Asia)
Chang Yu Pan (2014)
10.1111/j.1463-1326.2012.01606.x
Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta‐analysis
S-C Liu (2012)
10.1177/1479164111408937
Cardiovascular safety of liraglutide assessed in a patient-level pooled analysis of phase 2—3 liraglutide clinical development studies
S. Marso (2011)
10.2337/dc14-0024
HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
B. Ahrén (2014)
10.1016/S0140-6736(15)60936-9
Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study
L. Blonde (2015)
10.1016/S2213-8587(14)70029-4
Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
M. Diamant (2014)
10.21037/atm.2017.11.10
Semaglutide seems to be more effective the other GLP-1Ras.
Jens Juul Holst (2017)
10.1016/J.JCJD.2017.08.018
Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial
E. Raff (2017)
10.1111/dom.12406
Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes
D. D’Alessio (2015)
10.1016/j.jdiacomp.2014.01.012
Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S).
J. Rosenstock (2014)
10.1172/JCI75276
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
A. Secher (2014)
10.2147/CLEP.S113211
Nationwide trends in glucose-lowering drug use, Denmark, 1999–2014
Diana H Christensen (2016)
Dulaglutide treatment reduces glycaemic excursions in people with diabetes: a post‐hoc analysis of 6 phase 3 randomised clinical trials
V Pechtner (2017)
10.1111/dom.12121
Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal‐P)
M. Pinget (2013)
Pancreatic hyperenzymemia: clinical significance and diagnostic approach.
L. Frulloni (2005)
10.1007/s00125-015-3795-1
Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
M. Nauck (2015)
10.1111/j.1572-0241.2002.05766.x
A critical evaluation of laboratory tests in acute pancreatitis
D. Yadav (2002)
10.1155/2011/601047
Glucagon-Like Peptide-1 Gene Therapy
A. M. Rowzee (2011)
Trulicity (dulaglutide) prescribing information. Updated 1 August 2017
Eli Lilly (2018)
Trulicity (dulaglutide) European summary of product characteristics. Updated 23 May 2018
Eli Lilly (2018)
10.4158/CS-2017-0153
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2018 EXECUTIVE SUMMARY.
A. Garber (2018)
10.1124/JPET.103.051987
Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db Mice
C. Thorkildsen (2003)
10.1111/dom.12602
Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once‐daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study
M. Odawara (2016)
10.2337/dc13-2855
Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study
Lawrence A Leiter (2014)
10.1007/s00125-014-3360-3
HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea
P. Weissman (2014)
10.1111/dme.12328
Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1)
G. Bolli (2014)
10.1056/NEJMc1611289
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
J. Buse (2016)
10.2337/dc17-0417
Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
A. Ahmann (2017)
10.1016/j.toxicon.2010.12.016
The development of Byetta (exenatide) from the venom of the Gila monster as an anti-diabetic agent.
B. Furman (2012)
10.1002/dmrr.1080
Engineering and characterization of the long‐acting glucagon‐like peptide‐1 analogue LY2189265, an Fc fusion protein
W. Glaesner (2010)
10.1111/j.1464-5491.2010.03020.x
Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial
R. Ratner (2010)
10.1016/S2213-8587(17)30412-6
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
M. Bethel (2018)
10.1210/jc.2010-2822
Liraglutide treatment is associated with a low frequency and magnitude of antibody formation with no apparent impact on glycemic response or increased frequency of adverse events: results from the Liraglutide Effect and Action in Diabetes (LEAD) trials.
J. Buse (2011)
10.1016/S2213-8587(17)30085-2
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
V. Aroda (2017)
10.1111/j.1463-1326.2012.01560.x
GLP‐1 based therapies: differential effects on fasting and postprandial glucose
M. Fineman (2012)
10.1373/CLINCHEM.2003.024802
IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: a method-comparison study.
W. Hoelzel (2004)
Bydureon (exenatide extended release) European summary of product characteristics. Updated 19 January 2018
AB AstraZeneca (2018)
10.2147/PPA.S90842
Evaluating preferences for profiles of GLP-1 receptor agonists among injection-naïve type 2 diabetes patients in the UK
H. Gelhorn (2015)
10.1111/j.1742-1241.2011.02656.x
One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
R. Pratley (2011)
10.1007/s11892-010-0102-x
Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide?
M. Christensen (2010)
10.1016/S2213-8587(17)30013-X
Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
Christopher H. Sorli (2017)
10.1111/dom.12634
A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD‐8)
K. Dungan (2016)
10.1016/J.JCJD.2016.08.116
Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5)
Robin Conway (2016)
10.1056/NEJMoa1612917
Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
R. Holman (2017)
10.1007/s40618-014-0137-y
GLP-1: benefits beyond pancreas
Giovanna Muscogiuri (2014)
10.1053/J.GASTRO.2004.04.063
Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure.
L. Baggio (2004)
10.1016/S0140-6736(08)61206-4
Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
D. Drucker (2008)
Tanzeum® (albiglutide) US. Prescribing Information
GlaxoSmithKline LLC (2018)
10.1016/S0140-6736(12)61267-7
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
J. Buse (2013)
10.1111/dom.12479
Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study
R. S. Weinstock (2015)



This paper is referenced by
10.1007/s40261-019-00826-0
Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features
Katherine A. Lyseng-Williamson (2019)
10.3390/ijms20235831
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
Vjera Ninčević (2019)
10.3390/nu11112666
The Effects of a Whey Protein and Guar Gum-Containing Preload on Gastric Emptying, Glycaemia, Small Intestinal Absorption and Blood Pressure in Healthy Older Subjects
H. Pham (2019)
The Role Of The Central Glp-1 System In Cocaine-Seeking Behavior
Nicole Sachi Hernandez (2019)
10.3389/fbioe.2020.00880
Drug Delivery System in the Treatment of Diabetes Mellitus
Ruichen Zhao (2020)
10.3389/fnins.2020.00785
PT320, Sustained-Release Exendin-4, Mitigates L-DOPA-Induced Dyskinesia in a Rat 6-Hydroxydopamine Model of Parkinson’s Disease
Seong-Jin Yu (2020)
10.1016/j.brainres.2019.146562
Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1
Jerlhag Elisabet (2019)
10.1002/dmrr.3168
Glucagon‐like peptide‐1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
L. Cheng (2019)
10.1177/2050640620925968
Liraglutide accelerates colonic transit in people with type 1 diabetes and polyneuropathy: A randomised, double-blind, placebo-controlled trial
Anne-Marie Langmach Wegeberg (2020)
10.1007/s13300-019-0615-5
GLP-1 RA Treatment and Dosing Patterns Among Type 2 Diabetes Patients in Six Countries: A Retrospective Analysis of Pharmacy Claims Data
Vincent Divino (2019)
10.1007/s13300-020-00765-6
Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen
Yukiko Onishi (2020)
10.3390/ijms21051746
Liraglutide Protects Against Brain Amyloid-β1–42 Accumulation in Female Mice with Early Alzheimer’s Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation
A. Duarte (2020)
10.1016/j.metabol.2019.154045
Differential indication for SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with established atherosclerotic heart disease or at risk for congestive heart failure.
Francesco Giorgino (2019)
10.1016/j.physbeh.2019.03.026
Central GLP-1 receptors: Novel molecular targets for cocaine use disorder
N. Hernández (2019)
10.1007/s40265-020-01260-9
Dulaglutide: A Review in Type 2 Diabetes
Lesley J. Scott (2020)
10.1007/s13300-019-0625-3
Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents
R. Gentilella (2019)
10.1007/s13300-019-00726-8
Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study
Hitoshi Ishii (2019)
10.1016/j.bbrc.2018.11.135
Lixisenatide enhances mitochondrial biogenesis and function through regulating the CREB/PGC-1α pathway.
Zhen Zhao (2019)
10.1007/s12020-019-02055-z
GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials
Chuqing Cao (2019)
10.12688/f1000research.20602.1
Recent advances in understanding the role of glucagon-like peptide 1
Josh E. Reed (2020)
10.2337/cd19-0001
Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?
Robert H Eckel (2019)
10.2337/dc18-2648
Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide
J. Rosenstock (2019)
10.3390/nu12071962
Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution
Ryan Jalleh (2020)
10.5124/JKMA.2019.62.11.588
국내에서 현재 장기간 사용목적으로 선택할 수 있는 비만 치료약제의 작용기전과 임상응용
김 경곤 (2019)
10.4082/kjfm.19.0013
Understanding the Mechanism of Action and Clinical Implications of Anti-Obesity Drugs Recently Approved in Korea
Kyoung Kon Kim (2019)
10.1038/s41598-019-53356-2
Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon
Y. Li (2019)
10.1080/00325481.2019.1670017
Combination therapy with SGLT-2 inhibitors and GLP-1 receptor agonists as complementary agents that address multi-organ defects in type 2 diabetes
Rosemarie Lajara (2019)
10.1038/s41598-019-49757-y
Controlling Obesity and Metabolic Diseases by Hydrodynamic Delivery of a Fusion Gene of Exendin-4 and α1 Antitrypsin
Mingming Gao (2019)
10.1016/j.peptides.2019.170225
Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates
Patrick J. Knerr (2019)
10.1016/J.BRAINRES.2019.146562
Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1.
E. Jerlhag (2020)
10.1016/j.tem.2019.07.004
Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials
I. Caruso (2019)
10.1002/dmrr.3100
Diabetes pharmacotherapy and effects on the musculoskeletal system
Evangelia Kalaitzoglou (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar